Undisclosed Program in Oncology
Asset
Inhibits an undisclosed transcription factor.
- Stage
- Preclinical
- Modality
- Small molecule
- Target
- Not known
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Prostate cancer
Preclinical, altaytherapeutics.com, 10 Oct 2026
Sarcomas
Preclinical, altaytherapeutics.com, 10 Oct 2026
In the full profile
- Owner and partners1
- Competitors4
Every asset’s record: target, stage, trials and the evidence behind it.